Enanta Pharmaceuticals is a biotechnology company that engaged in the discovery and development of small molecule drugs for the treatment of viral infections. Co.'s primary wholly-owned research and development programs are in virology, namely respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, hepatitis B virus and human metapneumovirus. Co.'s out-licensed products include two protease inhibitors, which are developed through Co.'s Collaborative Development and License Agreement with AbbVie have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for hepatitis C virus. The ENTA stock yearly return is shown above.
The yearly return on the ENTA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ENTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|